Loading…
NextCure, Inc. is projected to decline to $5.40 by 2027, a -11% move from its current price of $6.07. NXTC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.68 | $6.07 | $6.48 | -0.07% |
| May 30 | $5.52 | $6.06 | $6.65 | -0.15% |
| May 31 | $5.40 | $6.06 | $6.79 | -0.22% |
| Jun 1 | $5.30 | $6.05 | $6.91 | -0.29% |
| Jun 2 | $5.22 | $6.05 | $7.01 | -0.37% |
| Jun 3 | $5.14 | $6.04 | $7.10 | -0.44% |
| Jun 4 | $5.07 | $6.04 | $7.19 | -0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.07 | $6.04 | $7.19 | -0.52% |
| Week 2 | $4.69 | $6.01 | $7.69 | -1.03% |
| Week 3 | $4.42 | $5.98 | $8.09 | -1.54% |
| Week 4 | $4.19 | $5.95 | $8.43 | -2.05% |
| Week 5 | $4.00 | $5.92 | $8.74 | -2.55% |
| Week 6 | $3.84 | $5.88 | $9.03 | -3.05% |
| Week 7 | $3.69 | $5.85 | $9.29 | -3.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on advancing medicines to treat cancer. The company’s product candidate is LNCB74, a B7-H4 targeted ADC to kill tumors.
It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors.
NextCure was incorporated in 2015 and is headquartered in Beltsville, Maryland. It operates within the Healthcare sector and focuses on developing therapies across multiple oncology and neuroscience targets.
NXTC is publicly traded with a current price of $6.07 and a market cap of $21.93M, holding a rank of 4871 among listed assets.
The near-term outlook shows a neutral stance in 2026, with an average price of $6.07, a high of $9.32, and a return on investment of 0, reflecting a flat expected path for that year. The sentiment remains NEUTRAL for 2026.
Over the longer horizon, the forecast depicts gradual upside into the 2030s and beyond, with the 2031–2050 series showing sustained positive momentum (e.g., 2031 avg $7.45 and 2032 avg $7.66, rising further toward 2050 with an avg of $22.32 and a max of $51.32). The forecast also notes periods of mixed sentiment, including bearish years early in the period, before a pronounced long-run upside. These are estimates, not guarantees, and carry inherent uncertainty.
A major floor 71.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 107.4% above — a clean break opens room to run.
A major ceiling 143.2% above — clearing it would confirm fresh momentum.
Key NXTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NXTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.15 | Sell | $7.64 | Sell |
| MA 10 | $8.89 | Sell | $8.45 | Sell |
| MA 20 | $9.25 | Sell | $9.16 | Sell |
| MA 50 | $10.26 | Sell | $10.15 | Sell |
| MA 100 | $11.43 | Sell | $10.56 | Sell |
| MA 200 | $9.98 | Sell | $10.31 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.46 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -278.65 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.30 | Sell |
| ROC (12) | -37.81 | Sell |
| Bollinger %B (20,2) | -0.23 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -1.94 | Sell |
| Ultimate (7,14,28) | 21.46 | Buy |
| Momentum (10) | -3.71 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 6.97 | Sell |
| ADX (14) | 16.17 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 30, signaling undersold conditions.
The asset is trading below the SMA50 of $10.26 and above the SMA200 of $9.98, suggesting a mixed near-term setup between shorter-term momentum and longer-term moving averages.
Support sits at $6.07 and resistance at $12.59, indicating a defined risk band around the current level. The 30-day range spans from $3.93 to $9.38, illustrating recent volatility within a relatively wide band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.07 | $6.07 | $9.32 | 0% | Neutral | |
| $3.89 | $5.40 | $8.12 | -11% | Neutral | |
| $3.38 | $4.99 | $7.97 | -18% | Bearish | |
| $3.39 | $5.26 | $8.82 | -13% | Neutral | |
| $3.40 | $5.53 | $9.64 | -9% | Neutral | |
| $4.38 | $7.45 | $13.43 | +23% | Bullish | |
| $4.32 | $7.66 | $14.23 | +26% | Bullish | |
| $3.96 | $7.30 | $13.94 | +20% | Bullish | |
| $3.74 | $7.18 | $14.06 | +18% | Neutral | |
| $3.11 | $6.20 | $12.42 | +2% | Neutral | |
| $3.79 | $8.43 | $18.53 | +39% | Bullish | |
| $10.04 | $22.32 | $51.32 | +268% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.07 | $6.07 | $7.21 | +0.00% |
| June 2026 | $4.87 | $5.84 | $7.26 | -3.80% |
| July 2026 | $4.65 | $5.67 | $7.23 | -2.82% |
| August 2026 | $4.93 | $6.10 | $7.92 | +7.47% |
| September 2026 | $5.12 | $6.39 | $8.44 | +4.83% |
| October 2026 | $4.97 | $6.27 | $8.40 | -1.86% |
| November 2026 | $5.05 | $6.43 | $8.71 | +2.48% |
| December 2026 | $5.29 | $6.80 | $9.32 | +5.77% |
Click any year to see its month-by-month NXTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NextCure, Inc.'s 2026 outlook centres on $6.07, within a $6.07 to $9.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NXTC could reach as high as $8.12, with a base case around $5.40 and support toward $3.89 — roughly -11% from $6.07. A consolidation phase looks the most probable path here.
Expect NXTC to range from $3.38 to $7.97 through 2028. The $4.99 average target implies a -18% move from current prices. That is -8% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The NXTC price prediction for 2029 points to an average of $5.26 (low $3.39, high $8.82) — a potential decline of -13% on today's $6.07. A consolidation phase looks the most probable path here.
In 2030, NXTC is projected to trade between $3.40 and $9.64, averaging $5.53 — a potential decline of -9% from today's $6.07. That is up +5% on the projected 2029 average. Price action looks broadly range-bound.
NextCure, Inc.'s 2031 outlook centres on $7.45, within a $4.38 to $13.43 range. That is up +35% on the projected 2030 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NXTC could reach as high as $14.23, with a base case around $7.66 and support toward $4.32 — roughly +26% from $6.07. Momentum favours further upside here.
Expect NXTC to range from $3.96 to $13.94 through 2033. The $7.30 average target implies a +20% move from current prices. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The NXTC price prediction for 2034 points to an average of $7.18 (low $3.74, high $14.06) — a potential gain of +18% on today's $6.07. Price action looks broadly range-bound.
In 2035, NXTC is projected to trade between $3.11 and $12.42, averaging $6.20 — a potential gain of +2% from today's $6.07. That is -14% versus the projected 2034 average. A consolidation phase looks the most probable path here.
NextCure, Inc.'s 2040 outlook centres on $8.43, within a $3.79 to $18.53 range. That is up +36% on the projected 2035 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2050, NXTC could reach as high as $51.32, with a base case around $22.32 and support toward $10.04 — roughly +268% from $6.07. Buyers look set to stay in control over this stretch.
Investing $1,000 in NXTC today (≈ 164.744646 NXTC) could be worth
$3,676.3
+$2,676.3 (+268%) by 2050 · US Dollar
Based on the average projected NXTC price of $22.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NXTCwould be worth at today's price.
$1,000 invested in NXTC on May 27, 2025 (≈ 169.376699 NXTC) would be worth
$1,028.12
+$28.12 (+2.8%) today · 1.03× · US Dollar
Based on a NXTC entry price of $5.9 vs. today's $6.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.65 | $629.34 | -37.1% |
| 1 month ago | $9.62 | $630.98 | -36.9% |
| 3 months ago | $13 | $466.92 | -53.3% |
| 6 months ago | $14.09 | $430.8 | -56.9% |
| 1 year ago | $5.9 | $1,028.12 | +2.8% |
| All time (5.0y) ago | $93.24 | $65.1 | -93.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NXTC forecast.
Our base-case forecast reaches $12.00 around 2050.
Implied market cap at $12.00: $43.35M
The multi-year forecast outlines a cautious start to the decade, with 2030 showing an average price of $5.53, a min of $3.40, a max of $9.64, and a return of -8.9 with NEUTRAL sentiment. This reflects near-term headwinds before a shift toward growth in subsequent years.
In 2031 the average climbs to $7.45 with a max of $13.43 and a min of $4.38, delivering a 22.7% return and bullish sentiment. 2032 carries similar momentum (avg $7.66, max $14.23, min $4.32) with a 26.1%Return and bullish sentiment, followed by 2033 (avg $7.30, min $3.96, max $13.94) at 20.3% and bullish.
2034 shows a softer intermediate path (avg $7.18, min $3.74, max $14.06) with 18.4% and neutral sentiment, and 2035 (avg $6.20, min $3.11, max $12.42) at 2.2% with neutral sentiment. By 2040 the forecast strengthens again (avg $8.43, min $3.79, max $18.53) with 38.8% and bullish sentiment, and by 2050 the projection implies substantial upside (avg $22.32, min $10.04, max $51.32) at 267.6% and bullish sentiment. These figures illustrate the potential long-run upside but also the considerable uncertainty and risk inherent in such forecasts.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $5.53 with a min of $3.40 and a max of $9.64, and a return of -8.9. The sentiment is NEUTRAL.
Short-term forecasts are NEUTRAL with some years showing negative returns (e.g., 2028 at -17.8). Long-term prospects show potential upside, with 2050 averaging $22.32 and a max of $51.32 and a return of 267.6, but these are estimates and carry substantial uncertainty.
The forecast maximum reaches $51.32 in 2050, with an average of $22.32 and a return of 267.6, suggesting the possibility of a high-scenario outcome within the projection horizon.
Current price is $6.07 and market cap is $21.93M.
The 30-day range is from $3.93 to $9.38.
NextCure, Inc. Community Discussion
0Share your NextCure, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.